Thomas Scheffold
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thomas Scheffold has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Priska Binner
Institut für Herz-Kreislaufforschung, Universität Witten/Herdecke, Dortmund, Germany
2 shared publicationsAnastassia Dermintzoglou
Herzzentrum Duisburg, Duisburg, Germany
1 shared publication- Andreas Huge
Core Facility Genomic, Medical Faculty of Muenster, University of Muenster, Albert-Schweitzer-Campus 1, D3, Domagstrasse 3, 48149 Muenster, Germany
1 shared publication Birgit S. Budde
Cologne Center for Genomics and Institute for Genetics, University of Cologne, Cologne, Germany
1 shared publicationCarmen Selignow
Max-Planck-Institut für Herz- und Lungenforschung, Bad Nauheim, Germany
1 shared publication- Eberhard von Hodenberg
Internal Medicine/Cardiology, Heart Center Lahr/Baden, 77933 Lahr, Germany
1 shared publication
Latest Publications
- Open Access
- 8 October 2009
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 9 (1) , 48
Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention
Restenosis represents the major limiting factor for the long-term efficacy of percutaneous coronary intervention (PCI). Several genetic factors involved in the regulation of the vascular system have been described to play a role in the pathogenesis of restenosis. We investigated whether the EPHX2 K55R polymorphism, previously linked to significantly higher risk for coronary heart disease (CHD), was associated with the occurrence of restenosis after PCI. The association with incident CHD should have been confirmed and a potential correlation of the EPHX2 K55R variant to an increased risk of hypertension was analysed.
- 8 October 2009
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 9 (1) , 48
Open AccessVariation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention
Restenosis represents the major limiting factor for the long-term efficacy of percutaneous coronary intervention (PCI). Several genetic factors involved in the regulation of the vascular system have been described to play a role in the pathogenesis of restenosis. We investigated whether the EPHX2 K55R polymorphism, previously linked to significantly higher risk for coronary heart disease (CHD), was associated with the occurrence of restenosis after PCI. The association with incident CHD should have been confirmed and a potential correlation of the EPHX2 K55R variant to an increased risk of hypertension was analysed.
- Open Access
- 26 December 2007
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 2 (12) , e1362
Noncompaction of the Ventricular Myocardium Is Associated with a De Novo Mutation in the β-Myosin Heavy Chain Gene
Noncompaction of the ventricular myocardium (NVM) is the morphological hallmark of a rare familial or sporadic unclassified heart disease of heterogeneous origin. NVM results presumably from a congenital developmental error and has been traced back to single point mutations in various genes. The objective of this study was to determine the underlying genetic defect in a large German family suffering from NVM. Twenty four family members were clinically assessed using advanced imaging techniques. For molecular characterization, a genome-wide linkage analysis was undertaken and the disease locus was mapped to chromosome 14ptel-14q12. Subsequently, two genes of the disease interval, MYH6 and MYH7 (encoding the α- and β-myosin heavy chain, respectively) were sequenced, leading to the identification of a previously unknown de novo missense mutation, c.842G>C, in the gene MYH7. The mutation affects a highly conserved amino acid in the myosin subfragment-1 (R281T). In silico simulations suggest that the mutation R281T prevents the formation of a salt bridge between residues R281 and D325, thereby destabilizing the myosin head. The mutation was exclusively present in morphologically affected family members. A few members of the family displayed NVM in combination with other heart defects, such as dislocation of the tricuspid valve (Ebstein's anomaly, EA) and atrial septal defect (ASD). A high degree of clinical variability was observed, ranging from the absence of symptoms in childhood to cardiac death in the third decade of life. The data presented in this report provide first evidence that a mutation in a sarcomeric protein can cause noncompaction of the ventricular myocardium.
- 26 December 2007
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 2 (12) , e1362
Open AccessNoncompaction of the Ventricular Myocardium Is Associated with a De Novo Mutation in the β-Myosin Heavy Chain Gene
Noncompaction of the ventricular myocardium (NVM) is the morphological hallmark of a rare familial or sporadic unclassified heart disease of heterogeneous origin. NVM results presumably from a congenital developmental error and has been traced back to single point mutations in various genes. The objective of this study was to determine the underlying genetic defect in a large German family suffering from NVM. Twenty four family members were clinically assessed using advanced imaging techniques. For molecular characterization, a genome-wide linkage analysis was undertaken and the disease locus was mapped to chromosome 14ptel-14q12. Subsequently, two genes of the disease interval, MYH6 and MYH7 (encoding the α- and β-myosin heavy chain, respectively) were sequenced, leading to the identification of a previously unknown de novo missense mutation, c.842G>C, in the gene MYH7. The mutation affects a highly conserved amino acid in the myosin subfragment-1 (R281T). In silico simulations suggest that the mutation R281T prevents the formation of a salt bridge between residues R281 and D325, thereby destabilizing the myosin head. The mutation was exclusively present in morphologically affected family members. A few members of the family displayed NVM in combination with other heart defects, such as dislocation of the tricuspid valve (Ebstein's anomaly, EA) and atrial septal defect (ASD). A high degree of clinical variability was observed, ranging from the absence of symptoms in childhood to cardiac death in the third decade of life. The data presented in this report provide first evidence that a mutation in a sarcomeric protein can cause noncompaction of the ventricular myocardium.
- 1 September 2005
- Published by Springer Nature in Herz
- Vol. 30 (6) , 550-557
Hypertrophe Kardiomyopathie
Die hypertrophe Kardiomyopathie (HCM) zählt zu den primär von der Herzmuskulatur ausgehenden Erkrankungen und tritt überwiegend familiär mit autosomal-dominantem Erbgang auf. In der Mehrzahl der Fälle lässt sich eine Mutation in einem der bisher 14 bekannten Krankheitsgene nachweisen. Mit einer Prävalenz von 0,2% gilt die HCM als häufigste hereditäre Herzerkrankung. Die genetischen Ursachen, das klinische Bild sowie der klinische Verlauf sind äußerst heterogen. Für die Diagnostik kommt gegenwärtig der Echokardiographie der größte Stellenwert zu. Es bleibt abzuwarten, wie in absehbarer Zukunft die Magnetresonanztomographie sowie molekulargenetische Befunde bewertet werden. In Abhängigkeit von der Lokalisation, dem Ausmaß der Hypertrophie und in einigen Fällen auch von der Art der genetischen Ursache ist die Prognose sehr unterschiedlich. Der plötzliche Herztod (SD) gilt gerade bei Jugendlichen als größtes Risiko der Erkrankung. Eine systematische Stratifizierung von Patienten mit erhöhtem Risiko für einen SD ist dringend notwendig. Die Implantation eines AICD ist gegen den SD die wirksamste Präventivmaßnahme. Die medikamentöse Basistherapie (oligo)-symptomatischer Patienten nutzt gleichermaßen Calciumantagonisten und Therapy-Blocker. Bei höhergradiger Herzinsuffizienz wird auf die typische Herzinsuffizienztherapie zurückgegriffen, vor allem die Kombination mit β-Blockern und, bei Indikation, auch mit Antiarrhythmika. Bei höhergradiger Obstruktion der Ausflussbahn stehen die alkoholinduzierte transkoronare Ablation der Septumhypertrophie (TASH; Synonym: perkutane transluminale septale Myokardablation [PTSMA]) bzw. die chirurgische Myektomie zur Wahl. Nur wenige Patienten mit terminaler Herzinsuffizienz werden einer Herztransplantation unterzogen. Obwohl die HCM zu den am besten erforschten genetischen Herzerkrankungen zählt, liegen praktisch kaum prospektive Studien vor, die an einer repräsentativen Patientenpopulation leitliniengerechte Empfehlungen zur Diagnostik und Therapie der HCM ermittelt haben. Für die Praxis sehr hilfreich ist jedoch das ACC/ESC Expert Consensus Document. Somit besteht auf dem Gebiet der HCM weiterhin ein erheblicher Bedarf an systematischen prospektiven klinischen Studien. Hypertrophic cardiomyopathy (HCM) counts as one of primary diseases emanating from the myocardium. In approximately 60% of the cases a familial autosomal dominant trait of disease inheritance was determined. In the majority of the cases a mutation in one of the known 14 disease-causing genes could be proven. With a prevalence of 0.2% HCM is one of the most common genetic heart diseases. The genetic causes, the clinical manifestations as well as the clinical progression are heterogeneous. At present, echocardiography is the most important diagnostic tool. It remains to be seen how the results from magnetic resonance imaging and molecular genetic diagnosis will have impact on the disease management in the future. The prognosis varies according to the localization, the degree of hypertrophy and, in some cases, on the underlying genetic mutation. Sudden death (SD) is a significant risk of the disease in young people. A systematic stratification of patients at a higher risk of SD is desperately needed. The implantation of an AICD is the most effective preventive measure against SD. The basis medication therapy of symptomatic patients uses calcium antagonists or β-blockers. In high-degree heart failure the typical therapy is applied mainly in combination with β-blockers and, if indicated, also with antiarrhythmics. When a high degree of outflow obstruction is present, transcoronary ablation of septum hypertrophy (TASH; synonym: percutaneous transluminal septal myocardial ablation [PTSMA]) or myectomy Ercan be performed. Heart transplantion is performed only in very few patients with terminal heart failure. Even though HCM is one of the best-documented genetically based heart diseases, only a few prospective studies and registries have been established, which have produced guidelines and recommendations for diagnostics and therapy. The ACC/ESC Expert Consensus Document is very helpful in this respect. Therefore, there is still a great need for systematic prospective analyses in large patient populations.
- 1 September 2005
- Published by Springer Nature in Herz
- Vol. 30 (6) , 550-557
Hypertrophe Kardiomyopathie
Die hypertrophe Kardiomyopathie (HCM) zählt zu den primär von der Herzmuskulatur ausgehenden Erkrankungen und tritt überwiegend familiär mit autosomal-dominantem Erbgang auf. In der Mehrzahl der Fälle lässt sich eine Mutation in einem der bisher 14 bekannten Krankheitsgene nachweisen. Mit einer Prävalenz von 0,2% gilt die HCM als häufigste hereditäre Herzerkrankung. Die genetischen Ursachen, das klinische Bild sowie der klinische Verlauf sind äußerst heterogen. Für die Diagnostik kommt gegenwärtig der Echokardiographie der größte Stellenwert zu. Es bleibt abzuwarten, wie in absehbarer Zukunft die Magnetresonanztomographie sowie molekulargenetische Befunde bewertet werden. In Abhängigkeit von der Lokalisation, dem Ausmaß der Hypertrophie und in einigen Fällen auch von der Art der genetischen Ursache ist die Prognose sehr unterschiedlich. Der plötzliche Herztod (SD) gilt gerade bei Jugendlichen als größtes Risiko der Erkrankung. Eine systematische Stratifizierung von Patienten mit erhöhtem Risiko für einen SD ist dringend notwendig. Die Implantation eines AICD ist gegen den SD die wirksamste Präventivmaßnahme. Die medikamentöse Basistherapie (oligo)-symptomatischer Patienten nutzt gleichermaßen Calciumantagonisten und Therapy-Blocker. Bei höhergradiger Herzinsuffizienz wird auf die typische Herzinsuffizienztherapie zurückgegriffen, vor allem die Kombination mit β-Blockern und, bei Indikation, auch mit Antiarrhythmika. Bei höhergradiger Obstruktion der Ausflussbahn stehen die alkoholinduzierte transkoronare Ablation der Septumhypertrophie (TASH; Synonym: perkutane transluminale septale Myokardablation [PTSMA]) bzw. die chirurgische Myektomie zur Wahl. Nur wenige Patienten mit terminaler Herzinsuffizienz werden einer Herztransplantation unterzogen. Obwohl die HCM zu den am besten erforschten genetischen Herzerkrankungen zählt, liegen praktisch kaum prospektive Studien vor, die an einer repräsentativen Patientenpopulation leitliniengerechte Empfehlungen zur Diagnostik und Therapie der HCM ermittelt haben. Für die Praxis sehr hilfreich ist jedoch das ACC/ESC Expert Consensus Document. Somit besteht auf dem Gebiet der HCM weiterhin ein erheblicher Bedarf an systematischen prospektiven klinischen Studien. Hypertrophic cardiomyopathy (HCM) counts as one of primary diseases emanating from the myocardium. In approximately 60% of the cases a familial autosomal dominant trait of disease inheritance was determined. In the majority of the cases a mutation in one of the known 14 disease-causing genes could be proven. With a prevalence of 0.2% HCM is one of the most common genetic heart diseases. The genetic causes, the clinical manifestations as well as the clinical progression are heterogeneous. At present, echocardiography is the most important diagnostic tool. It remains to be seen how the results from magnetic resonance imaging and molecular genetic diagnosis will have impact on the disease management in the future. The prognosis varies according to the localization, the degree of hypertrophy and, in some cases, on the underlying genetic mutation. Sudden death (SD) is a significant risk of the disease in young people. A systematic stratification of patients at a higher risk of SD is desperately needed. The implantation of an AICD is the most effective preventive measure against SD. The basis medication therapy of symptomatic patients uses calcium antagonists or β-blockers. In high-degree heart failure the typical therapy is applied mainly in combination with β-blockers and, if indicated, also with antiarrhythmics. When a high degree of outflow obstruction is present, transcoronary ablation of septum hypertrophy (TASH; synonym: percutaneous transluminal septal myocardial ablation [PTSMA]) or myectomy Ercan be performed. Heart transplantion is performed only in very few patients with terminal heart failure. Even though HCM is one of the best-documented genetically based heart diseases, only a few prospective studies and registries have been established, which have produced guidelines and recommendations for diagnostics and therapy. The ACC/ESC Expert Consensus Document is very helpful in this respect. Therefore, there is still a great need for systematic prospective analyses in large patient populations.